AI-powered
podcast player
Listen to all your favourite podcasts with AI-powered features
18min chapter
The Business Of CNS with Acumen's Jim Doherty, Ph.D.
Business Of Biotech
Sobernatug: A New Hope for Alzheimer's
This chapter explores the innovative approach of Acumen's lead candidate, Sobernatug, a monoclonal antibody targeting amyloid proteins linked to Alzheimer's disease. It discusses the therapy's unique focus on soluble A-beta oligomers and the transition from intravenous to subcutaneous administration to enhance patient convenience while addressing safety and efficacy concerns. The chapter also emphasizes the importance of biomarkers in early Alzheimer's diagnosis, the financial challenges faced by biotech companies, and the critical need for collaboration in drug development.
00:00
Transcript
Episode notes
Get the Snipd
podcast app
Unlock the knowledge in podcasts with the podcast player of the future.
AI-powered
Discover
highlights
Listen to the best highlights from the podcasts you love and dive into the full episode
Save any
moment
Hear something you like? Tap your headphones to save it with AI-generated key takeaways
Share
& Export
Send highlights to Twitter, WhatsApp or export them to Notion, Readwise & more
AI-powered
podcast player
Listen to all your favourite podcasts with AI-powered features
Discover
highlights
Listen to the best highlights from the podcasts you love and dive into the full episode